DHT helps explain why the prostate enlarges and why saw palmetto appears in so many prostate formulas. This guide breaks down the pathway in plain English.
By Dr. Marcus Reed, MD · Last Updated: July 23, 2026
The direct answer: DHT (dihydrotestosterone) is a potent androgen made from testosterone by the enzyme 5-alpha-reductase. Inside prostate tissue it binds androgen receptors roughly five times more strongly than testosterone and drives the cell growth behind benign prostatic hyperplasia. This is why both prescription 5-ARI drugs and natural ingredients like saw palmetto and beta-sitosterol target the same enzyme — reduce the conversion, reduce the growth signal.
To understand why the prostate enlarges, start with DHT. Once that pathway is clear, the rest of the picture becomes easier to follow. It explains why the problem arrives with age, why blood testosterone levels do not predict who gets symptoms, why the same hormone is implicated in male pattern baldness, and why almost every prostate supplement leads with saw palmetto. This is how the pathway works and what can realistically be done about it.
Testosterone is the better-known male hormone, but in several tissues it functions largely as a precursor. The enzyme 5-alpha-reductase converts it into dihydrotestosterone, which binds the androgen receptor with roughly five times the affinity and dissociates far more slowly. In practical terms, DHT is the more powerful signal.
There are two main isoforms. Type 1 is found mostly in skin and liver; type 2 dominates in the prostate, seminal vesicles and hair follicles. This tissue distribution is why DHT contributes to both prostate growth and male pattern baldness — same hormone, different tissues, opposite visible consequences.
Only about 5% of circulating testosterone converts to DHT systemically. But inside the prostate, local conversion is far higher, and DHT concentrations in prostate tissue substantially exceed testosterone concentrations. The key point is simple: prostate growth is governed by what happens locally inside the gland, not by your blood testosterone number.
Within prostate cells, DHT binds the androgen receptor, the complex moves to the nucleus, and it switches on genes promoting cell proliferation and suppressing programmed cell death. Over decades more cells are produced than removed and the gland grows. This is hyperplasia — an increase in cell number — which is why the condition is called benign prostatic hyperplasia rather than hypertrophy.
Two observations confirm the mechanism convincingly. Men who lack functional 5-alpha-reductase type 2 due to a rare genetic condition have small prostates and do not develop BPH. And men castrated before puberty do not develop it either. The androgen signal is necessary for the process.
There is a second layer worth knowing. As men age, the balance between androgens and estrogens shifts, and estrogen appears to sensitise prostate tissue to DHT's growth signal. This helps explain the timing — why prostates grow throughout adulthood but symptoms typically emerge in the fifties and sixties, when the hormonal ratio has drifted.
Men often notice the overlap and wonder if it is coincidence. It is not. DHT causes prostate cells to proliferate and, in genetically susceptible scalp follicles, causes the opposite — follicular miniaturization, producing progressively finer hairs until the follicle stops producing visible hair. Same hormone, opposite tissue response.
This is also why finasteride is prescribed at 5 mg for BPH and 1 mg for male pattern hair loss. One drug, one enzyme, two indications. It is a useful mental shortcut: anything meaningfully lowering DHT tends to affect both the prostate and the hairline.
Finasteride and dutasteride block the enzyme directly. Finasteride primarily inhibits type 2; dutasteride inhibits both isoforms and lowers serum DHT more completely. Over six to twelve months these drugs can reduce prostate volume by roughly 20-25% and improve symptom scores.
They are effective but not consequence-free. Reported side effects include reduced libido, erectile difficulty and ejaculatory changes in a minority, and a small proportion report persistent effects. They also lower PSA by roughly half, which must be accounted for when interpreting screening results. And they are slow — unlike alpha-blockers, which relieve symptoms within days by relaxing smooth muscle, 5-ARIs work by shrinking tissue and take months.
None of this is an argument against them. For men with measurably enlarged prostates and significant symptoms they are a well-evidenced option. It is an argument for having the conversation with a doctor who can weigh your specific situation.
The pharmacological logic — inhibit the enzyme, reduce the growth signal — is exactly what natural prostate ingredients attempt at a gentler magnitude.
Laboratory work indicates saw palmetto's fatty acid and sterol fraction can inhibit both isoforms of 5-alpha-reductase, and it also appears to interfere with DHT binding to androgen receptors. Clinical results have been mixed, largely a story about extract quality since only liposterolic extracts standardized for fatty acid content resemble what was used in positive studies. A randomized trial of a natural-product combination including saw palmetto reported significantly reduced nocturia and frequency (PMID 12092634).
The primary plant sterol in saw palmetto and many other plants. It inhibits 5-alpha-reductase, behaving in the same direction as finasteride though far more weakly, and has its own BPH evidence base (PMID 38148931). A phytosterol-enriched saw palmetto oil outperformed conventional saw palmetto oil in a randomized placebo-controlled trial (PMID 32620155).
A different point of intervention. Nettle root lignans appear to bind sex-hormone-binding globulin and show activity against aromatase, the enzyme converting testosterone to estradiol. Since the shifting androgen-to-estrogen ratio sensitises prostate tissue to DHT, this is a complementary angle rather than a duplicate of saw palmetto's mechanism.
Multi-ingredient formulas such as Prostate 911 combine these precisely because they hit different points in the same problem. The honest framing: these are mild modulators, not pharmaceutical-grade enzyme blockers. Expect gradual symptom support in mild-to-moderate cases, not the 20% volume reduction a prescription 5-ARI can achieve.
For most men with urinary symptoms, no — and understanding why is clarifying.
Serum DHT can be measured, but it tells you relatively little about what is happening inside the prostate. As covered above, growth is governed by local intraprostatic conversion, and tissue DHT concentrations do not track neatly with blood levels. Two men with identical serum DHT can have very different prostate volumes, because enzyme activity and receptor sensitivity inside the gland differ.
This is why urologists assess the prostate directly — symptom scores, physical examination, urine flow measurement, post-void residual volume, imaging where indicated — rather than ordering hormone panels. The functional question is how much the gland is obstructing flow, not what a hormone number reads.
There are exceptions. Androgen testing has a place in investigating suspected androgen deficiency, certain developmental disorders, or when monitoring particular therapies. But ordering a DHT test to work out whether your prostate is a problem is answering the wrong question with an expensive test.
Two misreadings are common and worth correcting.
First, lowering DHT is not automatically good. DHT is a normal, necessary hormone with roles in libido, erectile function and muscle. The goal in BPH is not eliminating it but moderating an excessive local growth signal in one tissue. Men sometimes stack multiple DHT-blocking supplements hoping for benefit and end up with sexual side effects instead.
Second, testosterone therapy and prostate risk are more nuanced than the old dogma. The long-standing assumption that raising testosterone raises prostate risk has been substantially revised in recent years, though it remains an area where you should follow a doctor's guidance rather than internet consensus. If you are on or considering TRT and have urinary symptoms, that is a conversation for a urologist.
The overall picture is reassuring rather than alarming. Prostate enlargement is a slow, well-understood, hormonally-driven process with a clear mechanism and a graded set of options. Knowing that DHT sits at the centre makes every option on the ladder — from a tomato-rich diet to a saw palmetto capsule to a prescription — easier to evaluate on its merits.
Key takeaway: DHT, converted from testosterone by 5-alpha-reductase, is the growth signal behind prostate enlargement. Prescription 5-ARIs block that enzyme strongly; saw palmetto, beta-sitosterol and nettle nudge the same pathway gently from different angles. Understand it as a signal to moderate, not a hormone to eliminate.
Saw palmetto, beta-sitosterol, pygeum, nettle and pumpkin seed in one daily formula. 90-day money-back guarantee.
Order from Official Website